Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia | MicrobiomeTrials
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-01-23Est. Completion: 2027-03-31
Enrollment target: 400 participants
Locations
UCLA DGSOM, UCLA Health, UCLA Semel Institute, Los Angeles, California, United States
University of Miami, Miller School of Medicine; Jackson Behavioral Health Hospital, Miami, Florida, United States
Grady Behavioral Health Center, -Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, United States
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Manhattan Psychiatric Center, The Nathan Kline Institute for Psychiatric Research, New York, New York, United States
Fundación para el Estudio y Tratamiento de las Enfermedades Mentales, Buenos Aires, Buenos Aires F.D., Argentina
Help Hospital, Vijayawada, Andhra Pradesh, India
Gauhati Medical College and Hospital, Guwahati, Assam, India
Masina Hospital Trust, Mumbai, Maharashtra, India
All India Institute Of Medical Sciences, Nagpur, Maharashtra, India
New Manak Healthcare Hospital, Navi Mumbai, Maharashtra, India
Ahana Hospitals LLP, Madurai, Tamil Nadu, India
All India Institute of Medical Sciences, Bībīnagar, Telangana, India
Other microbiome trials you might be interested in